Squamous Cell Carcinoma of the Head and Neck
179
15
24
90
Key Insights
Highlights
Success Rate
70% trial completion
Published Results
53 trials with published results (30%)
Research Maturity
90 completed trials (50% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 74/100
21.2%
38 terminated out of 179 trials
70.3%
-16.2% vs benchmark
9%
16 trials in Phase 3/4
59%
53 of 90 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 90 completed trials
Clinical Trials (179)
Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma
A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors
Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer
Ipilimumab for Head and Neck Cancer Patients
Neoadjuvant Treatment of Locally Advanced HNSCC With Pertuzumab Combined With Lenvatinib.
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
PEmbrolizumab Combined With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck
Nutrition and Life QUality Patients With Head and Neck Cancers
Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC
Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer
Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors
Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer
Priming Immunotherapy in Advanced Disease With Radiation
Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer
CIML NK Cell in Head & Neck Cancer
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck
Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer
Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy